These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 29577959)

  • 1. Sirtuin activators and inhibitors: Promises, achievements, and challenges.
    Dai H; Sinclair DA; Ellis JL; Steegborn C
    Pharmacol Ther; 2018 Aug; 188():140-154. PubMed ID: 29577959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New assays and approaches for discovery and design of Sirtuin modulators.
    Schutkowski M; Fischer F; Roessler C; Steegborn C
    Expert Opin Drug Discov; 2014 Feb; 9(2):183-99. PubMed ID: 24382304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Trends in Sirtuin Activator and Inhibitor Development.
    Bursch KL; Goetz CJ; Smith BC
    Molecules; 2024 Mar; 29(5):. PubMed ID: 38474697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis of Sirtuin 6 Inhibition by the Hydroxamate Trichostatin A: Implications for Protein Deacylase Drug Development.
    You W; Steegborn C
    J Med Chem; 2018 Dec; 61(23):10922-10928. PubMed ID: 30395713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using mitochondrial sirtuins as drug targets: disease implications and available compounds.
    Gertz M; Steegborn C
    Cell Mol Life Sci; 2016 Aug; 73(15):2871-96. PubMed ID: 27007507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of activity-based probes for the protein deacylase Sirt1.
    Goetz CJ; Sprague DJ; Smith BC
    Bioorg Chem; 2020 Nov; 104():104232. PubMed ID: 32911193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Preparation, Biochemical Analysis, and Structure Determination of Sirtuin Family Histone/Protein Deacylases.
    Suenkel B; Steegborn C
    Methods Enzymol; 2016; 573():183-208. PubMed ID: 27372754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dichotomous Sirtuins: Implications for Drug Discovery in Neurodegenerative and Cardiometabolic Diseases.
    Gomes P; Leal H; Mendes AF; Reis F; Cavadas C
    Trends Pharmacol Sci; 2019 Dec; 40(12):1021-1039. PubMed ID: 31704173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of NAD+ dependent histone deacetylases (sirtuins).
    Neugebauer RC; Sippl W; Jung M
    Curr Pharm Des; 2008; 14(6):562-73. PubMed ID: 18336301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of NAD+ dependent histone deacetylases (sirtuins) in ageing.
    Trapp J; Jung M
    Curr Drug Targets; 2006 Nov; 7(11):1553-60. PubMed ID: 17100594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirtuin activators and inhibitors.
    Villalba JM; Alcaín FJ
    Biofactors; 2012; 38(5):349-59. PubMed ID: 22730114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of activators and inhibitors of sirtuins.
    Balcerczyk A; Pirola L
    Biofactors; 2010; 36(5):383-93. PubMed ID: 20848588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and Specific Activators for Mitochondrial Sirtuins Sirt3 and Sirt5.
    Suenkel B; Valente S; Zwergel C; Weiss S; Di Bello E; Fioravanti R; Aventaggiato M; Amorim JA; Garg N; Kumar S; Lombard DB; Hu T; Singh PK; Tafani M; Palmeira CM; Sinclair D; Mai A; Steegborn C
    J Med Chem; 2022 Oct; 65(20):14015-14031. PubMed ID: 36228194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Current State of NAD
    Schiedel M; Robaa D; Rumpf T; Sippl W; Jung M
    Med Res Rev; 2018 Jan; 38(1):147-200. PubMed ID: 28094444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in characterization of human sirtuin isoforms: chemistries, targets and therapeutic applications.
    Cen Y; Youn DY; Sauve AA
    Curr Med Chem; 2011; 18(13):1919-35. PubMed ID: 21517779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of sirtuins in cellular homeostasis.
    Kupis W; Pałyga J; Tomal E; Niewiadomska E
    J Physiol Biochem; 2016 Sep; 72(3):371-80. PubMed ID: 27154583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slowing ageing by design: the rise of NAD
    Bonkowski MS; Sinclair DA
    Nat Rev Mol Cell Biol; 2016 Nov; 17(11):679-690. PubMed ID: 27552971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising drug discovery strategies for sirtuin modulators: what lessons have we learnt?
    Garg G; Singh AK; Singh S; Rizvi SI
    Expert Opin Drug Discov; 2021 Aug; 16(8):915-927. PubMed ID: 33880981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirtuins, resveratrol and the intertwining cellular pathways connecting them.
    Ungurianu A; Zanfirescu A; Margină D
    Ageing Res Rev; 2023 Jul; 88():101936. PubMed ID: 37116286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirtuin activators.
    Alcaín FJ; Villalba JM
    Expert Opin Ther Pat; 2009 Apr; 19(4):403-14. PubMed ID: 19441923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.